Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig

Gene Therapy

Volumn 5, Issue 3, 1998, Pages 309-319

  Jooss, K ^a,b   Turka, L A ^a,c   Wilson, J M ^a,b,c,d  

^a Institute for Human Gene Therapy   (United States)

^b Department of Molecular Engineering ^*  (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d WISTAR INSTITUTE   (United States)

Author keywords

Adenoviral vectors; Cystic fibrosis; Gene therapy; Immunity; T cells

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; IMMUNE RESPONSE; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADENOVIRIDAE; ANIMALIA;

EID: 0031883333     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300595     Document Type: Article

References (31)

1. Kozarsky KF, Wilson JM. Gene therapy of hypercholesterolemic disorders. Trends Cardiovasc Med 1995; 5: 205-209.
2. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
3. Zsengeller Z et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457-467.
4. Dai Y at al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
5. Yang Y, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenovirus. Immunity 1994; 1: 433-442.
6. Yang Y et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J Virol 1995; 69: 2004-2015.
7. Kozarsky KF et al. In vivo correction of LDL receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-13702.
8. Smith TAG et al. Adenovirus-mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 1993; 5: 397-402.
9. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
10. Yang Y et al. Up-regulation of class I major histocompatibility complex antigens by Interferon γ is necessary for T cellmediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 7257-7261.
11. Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76: 275-285.
12. Durie FH et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15: 406-411.
13. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996; 273: 1862-1864.
14. Larsen CP et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381: 434-438.
15. Kay MA et al. Long-term hepatic adenovirus mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
16. Fang B et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirusmediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
17. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-1566.
18. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 3: 412-420.
19. Gimmi CD et al. Human T cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586-6590.
20. Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenoviral vectors in mouse liver and lung. J Virol 1996; 70: 6370-6377.
21. Hancock W et al Stimulatory function and expression of CD40 ligand, CD80, CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996; 93: 13967-13972.
22. Jenkins MA. The ups and downs of T cell costimulation. Immunity 1994; 1: 443-448.
23. Gribben JG et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995; 92: 811-815.
24. Tivol EA et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-547.
25. Waterhouse P et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-988
26. Walunas TL et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
27. Baliga P et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994; 58: 1082-1090.
28. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-1227.
29. Linsley PS et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792-795.
30. Turka L et al. T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102-11105.
31. Xiang Z et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against the rabies virus. Virology 1994; 199: 132-140.